These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 3495487)

  • 41. [Preparation of an anti-human immunotoxin against bladder carcinoma and its in vitro targeting cytotoxicity].
    Zhao C
    Zhonghua Zhong Liu Za Zhi; 1992 Mar; 14(2):109-11. PubMed ID: 1618077
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Assessment of ligand effects in intracellular trafficking of ricin A chain using anti-ricin hybridomas.
    Kornfeld SB; Leonard JE; Mullen MD; Taetle R
    Cancer Res; 1991 Mar; 51(6):1689-93. PubMed ID: 1998959
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sensitivity of target cells to immunotoxins: possible role of cell-surface antigens.
    Colombatti M; Bron C
    Immunology; 1985 Jun; 55(2):331-8. PubMed ID: 2861156
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A novel designed single domain antibody on 3-D structure of ricin A chain remarkably blocked ricin-induced cytotoxicity.
    Shuntao W; Jiannan F; Jianwei G; Leiming G; Yan L; Yingxun S; Weisong Q; Meiru H; Gencheng H; Beifen S
    Mol Immunol; 2006 Apr; 43(11):1912-9. PubMed ID: 16343623
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease.
    Engert A; Burrows F; Jung W; Tazzari PL; Stein H; Pfreundschuh M; Diehl V; Thorpe P
    Cancer Res; 1990 Jan; 50(1):84-8. PubMed ID: 2152774
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neutralising antibodies against ricin toxin.
    Prigent J; Panigai L; Lamourette P; Sauvaire D; Devilliers K; Plaisance M; Volland H; Créminon C; Simon S
    PLoS One; 2011; 6(5):e20166. PubMed ID: 21633505
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunological characteristics associated with the protective efficacy of antibodies to ricin.
    Maddaloni M; Cooke C; Wilkinson R; Stout AV; Eng L; Pincus SH
    J Immunol; 2004 May; 172(10):6221-8. PubMed ID: 15128810
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro efficacy of anti-HIV immunotoxins targeted by various antibodies to the envelope protein.
    Pincus SH; Cole RL; Hersh EM; Lake D; Masuho Y; Durda PJ; McClure J
    J Immunol; 1991 Jun; 146(12):4315-24. PubMed ID: 1710247
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Correlation between in vivo toxicity and preclinical in vitro parameters for the immunotoxin anti-B4-blocked ricin.
    Grossbard ML; Lambert JM; Goldmacher VS; Blättler WA; Nadler LM
    Cancer Res; 1992 Aug; 52(15):4200-7. PubMed ID: 1379121
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Specific cytotoxicity of a human immunoglobulin-directed Fab'-ricin A chain conjugate.
    Raso V; Griffin T
    J Immunol; 1980 Dec; 125(6):2610-6. PubMed ID: 7430640
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Depletion of the helper/inducer (memory) T cell subset using a bispecific antibody-toxin conjugate directed against CD4 and CD29.
    Duke-Cohan JS; Morimoto C; Schlossman SF
    Transplantation; 1993 Nov; 56(5):1188-96. PubMed ID: 7504344
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High toxic efficiency of ricin immunotoxins specific for the T-cell antigen receptor of a human leukemia T-cell line.
    Izquierdo M; Balboa MA; Lamana ML; López-Botet M
    Int J Cancer; 1989 Apr; 43(4):697-702. PubMed ID: 2467887
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Resistance of myeloid leukaemia cell lines to ricin A-chain immunotoxins.
    Engert A; Brown A; Thorpe P
    Leuk Res; 1991; 15(11):1079-86. PubMed ID: 1961012
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Somatic cell mutants resistant to ricin, diphtheria toxin, and to immunotoxins.
    Goldmacher VS; Anderson J; Schulz ML; Blättler WA; Lambert JM
    J Biol Chem; 1987 Mar; 262(7):3205-9. PubMed ID: 2950096
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetics of an antibody-ricin conjugate administered intraperitoneally to mice.
    Brusa P; Dosio F; Pacchioni D; Delprino L; Grosa G; Bussolati G; Cattel L
    J Pharm Sci; 1994 Apr; 83(4):514-9. PubMed ID: 8046606
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cytotoxic effect of ricin A-chain conjugates containing monoclonal antibodies against human erythroid cells.
    Tonevitsky AG; Agapov II; Ershova GV; Sarma T; Toptygin AYu ; Mechetner EB
    Int J Immunopharmacol; 1993 Feb; 15(2):229-35. PubMed ID: 8468120
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of monoclonal antibody DF3 conjugated with ricin as a specific immunotoxin for in vitro purging of human bone marrow.
    Tondini C; Pap SA; Hayes DF; Elias AD; Kufe DW
    Cancer Res; 1990 Feb; 50(4):1170-5. PubMed ID: 2404589
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Cytotoxicity of a conjugate of ricin A-chain and monoclonal anti-allotypic antibody].
    Rachmanova VA; Tonevitskiĭ AG; Cherapakhin VV; Bobreneva RA
    Biull Eksp Biol Med; 1988 May; 105(5):568-70. PubMed ID: 3132992
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Target ricin by coupling to an anti-macrophage monoclonal antibody.
    Kaminski NE; Roberts JF; Guthrie FE
    J Immunopharmacol; 1986; 8(1):15-37. PubMed ID: 3086461
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ricin A-chain containing immunotoxins directed against different epitopes on the CD2 molecule differ in their ability to kill normal and malignant T cells.
    Press OW; Martin PJ; Thorpe PE; Vitetta ES
    J Immunol; 1988 Dec; 141(12):4410-7. PubMed ID: 2461993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.